Neuromuscular Research · Clinical Trial Update
Hawaii ALS & Neuromuscular Center Selected to Investigate Povetacicept in Generalized Myasthenia Gravis
A milestone for Hawaii patients, caregivers, and the neuromuscular research community
The Hawaii ALS & Neuromuscular Center team — bringing world-class neuromuscular research to the Pacific.
The Hawaii ALS and Neuromuscular Center and the Neuromuscular Research Unit have been selected as a clinical site for the ETNA study — a pivotal Phase 2 trial evaluating povetacicept in adults with Generalized Myasthenia Gravis (gMG). This selection underscores Hawaii's growing role in advancing cutting-edge neurological therapies for patients across the Pacific.
Understanding Generalized Myasthenia Gravis
According to the Myasthenia Gravis Foundation of America, Generalized Myasthenia Gravis (gMG) is the most prevalent form of the disease, representing approximately 85% of all MG cases. It is a chronic autoimmune neuromuscular disorder in which the immune system produces antibodies that mistakenly attack the acetylcholine receptors (AChR) at the neuromuscular junction, impairing the signals between nerves and muscles.
Droopy eyelids (ptosis) & double vision
Difficulty speaking & swallowing
Difficulty breathing
Generalized muscle weakness
Problems chewing
Trouble with everyday tasks
The Science Behind Povetacicept
Povetacicept represents a novel therapeutic approach rooted in neuroimmunology. It is an engineered fusion protein designed as a dual inhibitor of two cytokines — BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). Both of these signaling molecules are critical drivers of B-cell activation and the subsequent production of self-reactive antibodies — the very antibodies responsible for the neuromuscular damage seen in gMG.
Povetacicept mechanism of action: dual neutralization of BAFF and APRIL to suppress pathogenic antibody production.
Preclinical Research Highlights
Studies published in Frontiers in Immunology demonstrated that povetacicept:
- Significantly improved clinical disease activity in animal models of MG
- Reduced pathogenic anti-AChR autoantibody levels, targeting the core mechanism of the disease
- Outperformed existing treatments, including CD20 depletion and FcRn inhibition, in preclinical models
By simultaneously blocking both BAFF and APRIL, povetacicept may offer a more comprehensive suppression of the aberrant immune response than single-target therapies — opening a potentially transformative path for patients who have not found adequate relief with current standard-of-care treatments.
The ETNA Study: Trial Overview
The ETNA study is a Phase 2 clinical trial sponsored by Vertex Pharmaceuticals evaluating the safety and efficacy of povetacicept in adults with gMG. Enrollment is expected to begin in the first half of 2026.
Trial Design
Multicenter · Randomized · Double-blind · Placebo-controlled · Long-term extension
Participant Eligibility
Ages 18–80 · Generalized MG · MGFA Clinical Classification II–IV
Sponsor
Vertex Pharmaceuticals
Phase
Phase 2 — Safety & Efficacy
"
Our Hawaii patients, caregivers, families, neurologists & researchers are honored to contribute to the development of Novel Neuromuscular Therapy.
Hawaii's Role in Advancing Neuromuscular Research
Being selected as a site for the ETNA trial is a testament to the clinical expertise and research infrastructure built by the Hawaii ALS and Neuromuscular Center. Dr. Gonzalez holds dual fellowship training in both Neuromuscular Medicine and Neuroimmunology — a specialized combination uniquely suited to leading research into immune-mediated neuromuscular diseases like gMG.
The center is also a proud member of the MG Foundation of America Partners in MG Care network, reflecting a sustained commitment to best practices and patient-centered care for the myasthenia gravis community across the Hawaiian islands and the broader Pacific region.
Participation in trials like ETNA ensures that local patients do not have to travel to the continental United States to access potentially life-changing therapies — bringing world-class neuroscience to the heart of the Pacific.
Are You or a Loved One a Candidate?
Enrollment for the ETNA Trial Is Expected to Begin in 2026
If you are between 18 and 80 years old with a confirmed diagnosis of Generalized Myasthenia Gravis (MGFA Classification II–IV), you may be eligible. Contact our dedicated Neuromuscular Research Hotline to learn more.
About the Center
The Hawaii ALS and Neuromuscular Center is a member of the MG Foundation of America Partners in MG Care network — combining compassionate patient care with active participation in clinical research to ensure Hawaii patients have access to the latest advances in neuromuscular medicine. Dedicated Neuromuscular Research Hotline: (808) 564-6141
